Biomarkers of Systemic Inflammation in Stable and Exacerbation Phases of COPD
Biomarkers of Systemic Inflammation in Stable and Exacerbation Phases of COPD
复制标题
DOI：
10.1007/s00408-008-9106-6
复制
发表时间：
2008-12-01
期刊：
影响因子：
5
通讯作者：
Ozcan, Hatice
中科院分区：
文献类型：
--
作者：
Karadag, Fisun;Karul, Aslihan B.;Ozcan, Hatice
除了对肺部的有害影响外，慢性阻塞性肺疾病（COPD）应被视为一种涉及多个器官和系统的复杂全身性疾病。COPD中全身性炎症的性质和过程很重要，因为存在抗炎治疗的潜力。本研究的目的是评估COPD患者与健康对照组相比稳定期和加重期全身炎症的生物标志物。我们还研究了COPD急性加重后这些生物标志物的变化过程，以评估其对疾病监测的有用性。纳入了83例中度至极重度COPD稳定患者、20例急性加重期患者和30例肺功能正常的受试者。在随访期间，在稳定期COPD患者和对照组中测量一次血清肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）和一氧化氮（NO）水平，在COPD急性加重组中测量三次。稳定组和急性加重组的TNF-α和IL-6水平均高于对照组。虽然稳定期COPD组的NO水平并不高于对照组，但急性加重组的NO水平高于对照组。在急性加重期后的随访中，与入院时相比，未检测到细胞因子或NO水平的显著变化。TNF-α和IL-6的血清水平升高支持其用作稳定型COPD患者全身炎症反应的生物标志物。然而，我们所研究的循环生物标志物并没有被发现是有用的，无论是作为COPD急性加重的指标或监测恶化后的恢复。
Apart from the deleterious effects on the lungs, chronic obstructive pulmonary disease (COPD) should be considered a complex, systemic disease involving several organs and systems. The nature and course of systemic inflammation in COPD is important since there is a potential for anti-inflammatory therapy. The objective of the current study was to assess biomarkers of systemic inflammation in stable and exacerbation phases of COPD patients as compared to healthy controls. We also investigated the course of these biomarkers after COPD exacerbation to evaluate their usefulness for disease monitoring. Eighty-three stable patients with moderate to very severe COPD, 20 patients in exacerbation phase, and 30 subjects with normal pulmonary function were included. Serum tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and nitric oxide (NO) levels were measured once in stable COPD patients and controls and three times in the COPD exacerbation group during follow-up. TNF-alpha and IL-6 levels were higher than in controls in both stable and exacerbation groups. Although NO was not higher in the stable COPD group than in controls, it was higher in the exacerbation group. In follow-up after the exacerbation period, significant alteration was not detected in cytokine or NO levels compared to admission. Raised serum levels of TNF-alpha and IL-6 support their use as biomarkers of the systemic inflammatory response in stable COPD patients. However, the circulating biomarkers we have studied are not found to be useful either as indicators of COPD exacerbation or for monitoring recovery after exacerbation.